Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of SHR-1819 in adolescents with moderate-to-severe atopic dermatitis
CTR20255058Phase 3Active
- Sponsor
- Hengrui Therapeutics
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of SHR-1819 in atopic dermatitis (AD), sponsored by Hengrui Therapeutics. Started Mar 2026; status: active.
02
Drugs
SHR-1819
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20255058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255058.